NEW YORK – Protein expression firm Nuclera said Wednesday that it has closed a $75 million Series C funding round.
The round was led by Elevage Medical Technologies, backed by Patient Square Capital, and joined by British Patient Capital, Cambridge Innovation Capital, Jonathan Milner, GK Goh, M&G Catalyst, E Ink, Michael McCreary, Uni Power Group, and Verve Ventures.
Nuclera, based in Cambridge, UK, said it will use the funds to support commercialization of its eProtein Discovery benchtop protein expression and purification system.
The eProtein Discovery system automates protein construct screening and allows for the cell-free production of milligram amounts of protein in less than 48 hours. The system has been installed at contract research organizations and biopharma firms as well as academic institutions including University College London, University of Cambridge, University of Southampton, University of Manchester, Flanders Institute for Biotechnology in Belgium, and the CRUK Cambridge Institute.
"Nuclera has developed a solution for one of the leading obstacles in drug discovery: access to proteins that are needed throughout the drug discovery process," Elevage Chief Operating Officer Michael Wasserman said in a statement. "The demand for Nuclera's technology is expanding rapidly, as AI and structural biology continues to drive the pace of new discoveries in life sciences and drug development."
"This significant investment demonstrates continued confidence in our team, our eProtein Discovery system, and our potential to revolutionize the way proteins are made," Michael Chen, Nuclera's cofounder and CEO, said in a statement. "This funding will accelerate our mission to provide ready-to-use benchtop protein screening and making tools to empower protein scientists around the world."
The new financing follows a $42.5 million Series B round the company closed in 2022.